Figure 3.

The DcNP approach provides opportunities for effective and safe treatment of MBC. A. Schematic representation of how GT DcNP enhances tumor tissue and cell selectivity and likely mechanisms that lead to enhanced exposure and extension of effective drug concentrations in metastatic breast cancer cells (Jesse Yu, 2020). B. Association of GT to DcNPs increases the concentration of GT in plasma over time compared to CrEl control suspension (J. Yu, Mu, et al., 2020). Doses: 50/5 mg/kg G/T. C. Enhancement of GT fixed-dose combination treatment on MBC in the lung by DcNP (Mu, et al., 2020). Mice with IV inoculation of 4T1-luc to form lung metastasis were administered with a single IV bolus dose of 50/5 mg/kg GT combination in DcNP or CrEL control formulation. On day 14, the total tumor burden was examined by bioluminescence of luciferase transfected cancer cells. Contents in this figure were reproduced with permission of publishers.